Table 3.
Estimates of the steady-state exposure of alogliptin 25 mg QD
| Statistic | AUC0–t (ng·h/ml) | Cmax (ng/ml) |
|---|---|---|
| N | 74 | 74 |
| Mean (SD) | 1380 (1240) | 118 (54.4) |
| Geometric mean (%CV) | 1158 (54.6) | 110 (37.6) |
| 95% CI of geometric mean | 1030, 1301 | 101, 119 |
| 5th percentile | 577 | 65.4 |
| 10th percentile | 663 | 73.8 |
| 25th percentile | 880 | 92.1 |
| 50th percentile | 1110 | 109 |
| 75th percentile | 1340 | 131 |
| 90th percentile | 1940 | 148 |
| 95th percentile | 2360 | 176 |
AUC0–t area under the curve to the end of the dosing period, CI confidence interval, Cmax maximum serum concentration, CV coefficient of variation, QD once daily, SD standard deviation